Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biopure Corporation has received regulatory authorization in the UK to initiate a phase II clinical trial of its investigational oxygen therapeutic Hemopure, which is designed to facilitate healing in patients undergoing lower limb amputation.
Subscribe to our email newsletter
The 100-patient clinical trial is designed to assess the product’s safety and feasibility in increasing the incidence of complete wound healing and reducing the incidence of subsequent amputations in patients with severe peripheral vascular disease who are undergoing lower limb amputation below or through the knee joint.
Biopure has also received regulatory authorizations in South Africa for this trial, in the UK for a proposed phase II cardiac surgery trial and in Belgium for a proposed phase II coronary angioplasty trial of the product. The company expects to initiate patient enrollment in these trials in late 2005 and early 2006.